Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Amyotrophic Lateral Sclerosis

What is Amyotrophic Lateral Sclerosis?

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disease caused by the degeneration of motor neurons.


Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disease caused by the degeneration of motor neurons.
Acknowledgement of Amyotrophic Lateral Sclerosis has not been added yet.
Synonyms for Amyotrophic Lateral Sclerosis has not been added yet.
Most individuals have a non-inherited sporadic form of ALS, but there is a small 5-10% of individuals who have familial ALS. This disease is caused by mutations in any of the following genes: C9orf72, SOD1, TARDBP, FUS, ANG, ALS2, SETX, and VAPB, where the inheritance patterns of these genes differ. The most common inheritance pattern of ALS is autosomal dominant.
Early symptoms of ALS such as muscle twitching, cramping, stiffness, and weakness are usually overlooked. However, symptoms may progress to slurred speech and difficulty chewing and swallowing (dysphagia). As ALS progresses, communication skills worsen, muscle strength decreases, and muscle tissue lose mass (atrophy), rendering individuals unable to use their hands and limbs for functions such as walking. Around 20% of individuals with ALS also develop frontotemporal dementia, which is a progressive brain disorder that affects personality, behaviour, and language. Ultimately, individuals with ALS die of respiratory failure.
ALS is diagnosed with the loss of motor neurons with intraneuronal ubiquitin-immunoreactive inclusions in upper motor neurons and TDP-43 immunoreactive inclusions in degenerating lower motor neurons.
Diagnostic tests of Amyotrophic Lateral Sclerosis has not been added yet
There is current no treatment available for ALS. However, ALS can be managed through relieving an individual of symptoms. Riluzole is the first drug approved by The Food and Drug Administration (FDA) that can prolong survival for 3-5 months. It cannot, however, delay the loss of motor neurons.
Prognosis of Amyotrophic Lateral Sclerosis has not been added yet.
Name Description
isisRGIIntern Due to dysphagia, eating may become a problem. However, adequate nutrition and fluids can be obtained with use of a gastric feeding tube and vitamin therapy. Physical therapy would also help maintain joint flexibility and prevent muscle contractures. Communication devices such as artificial speech articulation, “The Talking Board”, and the “Etran Board” would be useful for people who have lost their ability to speak.
References of Amyotrophic Lateral Sclerosis has not been added yet.
contact Created by asmnm
Last updated 18 Oct 2008, 08:53 PM

Posted by asmnm
18 Oct 2008, 08:53 PM

Hello All members

Community External News Link
Title Date Link
Could This Radical New Approach to Alzheimer’s Lead to a Breakthrough? 02/10/2019
25-year-old faces rare form of ALS that took her twin, but experimental drug offers hope 06/22/2019
Apic Bio’s APB-102 Receives Orphan Drug Designation from the FDA for the Treatment of Genetic SOD1 ALS 07/23/2019
Drew Brees gives emotional speech as Steve Gleason receives Congressional Gold Medal 01/18/2020
Community Resources
Title Description Date Link
ALS Therapy Development Institute

The ALS Therapy Development Institute is a nonprofit biotechnology company discovering treatments for patients alive today. Our approach combines the power of a nonprofit mission with the best practices of a for-profit biotechnology company: rigorous, open-minded research and proven drug development techniques.

The ALS Association

The ALS Association relentlessly pursues its mission to help people living with ALS and to leave no stone unturned in search for the cure of the progressive neurodegenerative disease that took the life and name of Baseball Legend Lou Gehrig.


Clinical Trials

Cords registry

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.

Enrolling is easy.

  1. Complete the screening form.
  2. Review the informed consent.
  3. Answer the permission and data sharing questions.

After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.

Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.

Visit to enroll.

Community Leaders


Expert Questions

Ask a question

Community User List

123Genetix is an innovative not-for-profit organization created to advance rare disease research with our predictive computer modeling technology. We believe that rare should not mean forgotten. To...

Pediatric Physical Therapist specializing in rare conditions and multiple disabilities
I am a family medicine physician with an interest in how to better diagnose rare disorders in the primary care setting. I would like to see family doctors work with their patients for prompt and...
I am involved in research and interested in shaping LGMD research to meet patients and doctors and physio needs. I am not a LGMD sufferer but rather a concerned scientist. I would understand from...
test account

Start a Community

Don't See Your Condition On Rareshare?

Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.


Have questions about rareshare?

Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.

Discussion Forum


Created by asmnm | Last updated 18 Oct 2008, 08:53 PM


Our Communities

Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.


Our Resources

Our rare disease resources include e-books and podcasts





Our Community Leaders

Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.